ELVN (Enliven Therapeutics) Earnings growth in current year

Official company branding of enliventherapeutics.com (ELVN)

High R&D expenditures and stringent FDA oversight create colossal barriers to capital. The YoY net income per share growth rate in the GURU.Markets chart clearly illustrates this dynamic, where the value 8.60 describes the current level. Enliven Therapeutics (ELVN) developments in overcoming drug resistance provide a unique advantage, while patients' critical dependence on the therapy guarantees one hundred percent retention within the ecosystem.

ELVN (Enliven Therapeutics, Inc.) Earnings growth in current year history from 04/28/2023 to 11/18/2026

Comprehensive metric breakdowns and analytics for Enliven Therapeutics (ELVN)

- share price and expert price forecast:
Fundamental valuation:ELVN Enliven Pharma
Signature product of Enliven Corp

The aggressive development of kinase inhibitors for leukemia therapy requires colossal expenditures, which is directly reflected in the annual net income per share dynamics for Enliven Therapeutics (ELVN). This metric, which has reached a value of 8.60, measures the year-over-year EPS growth rate, allowing investors to assess the efficiency of transforming R&D activity into actual financial results and avoid overpaying for unjustified optimism.

Direct competitors

GMAB: Net earnings per one share growth for the current year|EXEL (Exelixis Inc.) - Earnings growth in current year|Earnings growth in current year nuvalent.com|Earnings per share growth in current year Kymera (KYMR)|IDYA (IDEAYA Biosciences, Inc.) - Earnings per share increase in current year|Earnings growth in current year ORIC (ORIC Pharmaceuticals Inc)|Net earnings per share change in current year Relay Pharma|Nurix Therapeutics Inc - Earnings growth in current year|Earnings per share growth rate in current year Tyra Biosciences|VSTM (Verastem, Inc.) - Net earnings per share growth this year|GLUE: Net earnings per one share growth for the current year|CGEM (cullinanoncology.com) - Earnings growth in current year|Earnings per share growth rate in current year Immuneering Inc. IMRX|Earnings growth in current year CCCC|Black Diamond Therapeutics - Earnings per share growth this year|Repare Therapeutics Inc. - Net earnings per share growth this year|Earnings per share increase in current year PMVP|KPTI: Net earnings per share growth this year|propanc.com - Net earnings per one share growth for the current year|BGMS: Earnings growth in current year|Aadi Bioscience Inc - Earnings per share increase in current year|ALRN (Aileron Therapeutics Inc) - Earnings growth in current year|Earnings per share growth rate in current year blueprintmedicines.com BPMC|Earnings per share growth in current year GlycoMimetics Inc. (GLYC)|SWTX (SpringWorks) - Earnings per share increase in current year